Compare GE Vernova Inc (GEV) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance

GE Vernova (GEV) trades at $997.09, down 3.12% today but maintains strong analyst support with 22 buy ratings and a $1,270 consensus price target. The stock shows bullish technical signals with support at $985 and resistance at $1,005. Recent earnings beat expectations in Q4 2025 and Q1 2026, though Q2 2026 missed estimates. The company benefits from AI-driven power demand growth and secured the first US construction permit for its BWRX-300 small modular reactor.

GEV presents compelling growth potential driven by AI infrastructure demand and nuclear energy expansion, with revenue projected to grow from $38.1B to $41.4B. However, elevated valuation multiples (P/E 28.59, EV/EBITDA 85.02) and execution risks in the wind power segment warrant caution. The strong analyst consensus and 45% YTD gain suggest continued momentum if operational targets are met.

Regeneron Pharmaceuticals (REGN) trades at $739.57, up 0.12% on the day, with a bearish technical signal but strong fundamental performance. Recent earnings have consistently beaten estimates, and the company maintains robust profitability with a net income margin of 27.86%. A major $8 billion expansion of the immunology alliance with Sanofi, announced October 1, 2026, provides significant future revenue potential and strategic momentum.

The outlook is positive, supported by strong earnings, a lucrative partnership, and a consensus analyst price target of $846. Key risks include competitive pressures in key drug markets and reliance on successful clinical trial outcomes. The stock presents a compelling opportunity for growth investors, though volatility may persist near-term.